ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Sunday, November 17, 2024

10:30AM-12:30PM: Abstract Number: 1476

Individualizing NSAIDs in Axial Spondyloarthritis Through a Series of N-of-1 Clinical Trials with Bayesian Analysis

SpA Including PsA – Treatment Poster II

10:30AM-12:30PM: Abstract Number: 0955

Inhibition of Interleukin-2-Inducible T Cell Kinase with Soquelitinib Demonstrates Efficacy in Preventing Lung Damage in Murine Models of Systemic Sclerosis

Systemic Sclerosis & Related Disorders – Basic Science Poster I

10:30AM-12:30PM: Abstract Number: 1067

Initiation of Urate-Lowering Therapy in Patients Hospitalized with Gout Flare at a Single Center: Opportunity for Quality Improvement

Measures & Measurement of Healthcare Quality Poster

10:30AM-12:30PM: Abstract Number: 1239

Innovative Patient Empowerment: Evaluating the Effect of a Physician-created Educational Video and To-do Lists on Promoting Preventive Health Measures in Rheumatic Disease Patients

Patient Outcomes, Preferences, & Attitudes Poster II

10:30AM-12:30PM: Abstract Number: 1064

Inpatient and Outpatient Palliative Care Referral Practices for Patients with Rheumatic Disease: Retrospective Chart Review at a Single Academic Medical Center

Measures & Measurement of Healthcare Quality Poster

10:30AM-12:30PM: Abstract Number: 1245

Inpatient Discontinuation of Allopurinol – A Quality Improvement (QI) Initiative

Patient Outcomes, Preferences, & Attitudes Poster II

10:30AM-12:30PM: Abstract Number: 1347

Interest of DAS28-γGT in Assessing Cardiovascular Risk Activity in Rheumatoid Arthritis in Routine Practice

RA – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 0901

Intergenic Alu Elements Are Uniquely Expressed in Dermatomyositis and Correlate with Interferon Stimulated Genes

Genetics, Genomics & Proteomics Poster

10:30AM-12:30PM: Abstract Number: 1608

Interstitial Lung Disease in ANCA-associated Vasculitis: A Retrospective Study of Clinical Characteristics, Radiographic Features, and Outcomes

Vasculitis – ANCA-Associated Poster II

10:30AM-12:30PM: Abstract Number: 1186

Intra-articular Corticosteroid Injections for Knee Osteoarthritis: Does the Dose Matter?

Osteoarthritis – Clinical Poster I

10:30AM-12:30PM: Abstract Number: 1626

Intracranial Giant Cell Arteritis: A Comprehensive Systematic Review

Vasculitis – Non-ANCA-Associated & Related Disorders Poster II

10:30AM-12:30PM: Abstract Number: 1258

Investigating Factors Associated with Gaps in Care in Adolescents and Young Adults with Systemic Lupus

Pediatric Rheumatology – Clinical Poster II

10:30AM-12:30PM: Abstract Number: 1329

Investigating Predictors of Transfusion in Rheumatoid Arthritis and Osteoarthritis Patients Undergoing Knee Arthroplasty

RA – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1107

Investigating Pyrexia of Unknown Origin: A Rheumatologist’s Perspective

Miscellaneous Rheumatic & Inflammatory Diseases Poster II

10:30AM-12:30PM: Abstract Number: 1282

Investigating the Genetics of Depression and Anxiety in Children and Adolescents with and Without Systemic Lupus Erythematosus

Pediatric Rheumatology – Clinical Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].